XML 50 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue (Tables)
 6 Months Ended
Oct. 28, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The table below illustrates net sales by segment and division for the three and six months ended October 28, 2022 and October 29, 2021:
 
Three months ended
Six months ended
(in millions)October 28, 2022October 29, 2021October 28, 2022October 29, 2021
Cardiac Rhythm & Heart Failure $1,431 $1,471 $2,824 $2,954 
Structural Heart & Aortic757 750 1,499 1,537 
Coronary & Peripheral Vascular 584 606 1,163 1,226 
Cardiovascular 2,773 2,827 5,486 5,717 
Surgical Innovations1,398 1,497 2,736 3,051 
Respiratory, Gastrointestinal, & Renal671 802 1,335 1,570 
Medical Surgical 2,070 2,299 4,071 4,621 
Cranial & Spinal Technologies1,081 1,067 2,124 2,189 
Specialty Therapies686 634 1,353 1,275 
Neuromodulation419 435 824 875 
Neuroscience 2,186 2,136 4,301 4,340 
Diabetes 556 585 1,098 1,157 
Total$7,585 $7,847 $14,955 $15,835 

The table below illustrates net sales by market geography for each segment for the three and six months ended October 28, 2022 and October 29, 2021:
 
U.S.(1)
Non-U.S. Developed Markets(2)
Emerging Markets(3)
Three months endedThree months endedThree months ended
(in millions)October 28, 2022October 29, 2021October 28, 2022October 29, 2021October 28, 2022October 29, 2021
Cardiovascular $1,424 $1,373 $802 $948 $546 $506 
Medical Surgical 905 970 719 841 446 488 
Neuroscience 1,512 1,394 382 433 292 309 
Diabetes 228 261 254 256 74 69 
Total$4,069 $3,997 $2,157 $2,478 $1,359 $1,372 
U.S.(1)
Non-U.S. Developed Markets(2)
Emerging Markets(3)
Six months endedSix months endedSix months ended
(in millions)October 28, 2022October 29, 2021October 28, 2022October 29, 2021October 28, 2022October 29, 2021
Cardiovascular $2,722 $2,793 $1,694 $1,952 $1,070 $972 
Medical Surgical 1,748 1,959 1,485 1,710 838 951 
Neuroscience 2,931 2,840 788 898 582 602 
Diabetes 434 506 518 519 145 132 
Total$7,835 $8,098 $4,485 $5,079 $2,635 $2,658 
(1)U.S. includes the United States and U.S. territories.
(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.
(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.